Clinical Trial

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety, tolerance, pharmacokinetics, and biological properties of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced solid tumors.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-06-21; most recent amendment 2026-02-24.
Status change: Recruiting → Active, Not Recruiting 2025-09-04
Status change: Not Yet Recruiting → Recruiting 2023-07-05
Trial Details
NCT Number NCT05914376
Lead Sponsor Hangzhou Converd Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 24 participants
Start Date 2023-07-05
Primary Completion 2025-07-02 (estimated)
Study Completion 2027-06-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-27